Controlled trial of thyrotropin releasing hormone tartrate in ataxia of spinocerebellar degenerations☆
References (21)
Treatment of senile dementia and cerebellar disorders with phthalazinol — Cyclic AMP-increasing agent, phthalazinol, in therapeutic trial in hitherto incurable morbid conditions, Part 1
Mech. Ageing and Develop.
(1976)Effect of thyrotropin-releasing hormone on ataxia of spinocerebellar degeneration
Lancet
(1980)Effects of thyrotropin releasing hormone on ataxic gait in Rolling mouse Nagoya
Igaku no Ayumi
(1977)Emerging treatments — Replacement therapy with choline or lecithin in neurological diseases
Can. J. Neurol. Sci.
(1978)Phosphatidylcholine (lecithin) in neurologic disorders
Neurology (Minneap.)
(1978)Effect of lecithin on disability and plasma free-choline levels in Friedreich's ataxia
J. Neurol. Neurosurg. Psychiat.
(1980)Physostigmine in familial ataxias
Neurology (Minneap.)
(1977)Double-blind, triple-crossover trial of low doses of oral physostigmine in inherited ataxia
Neurology (Minneap.)
(1981)Effects of substance P and baclofen on the familial paraplegia
Oral choline in cerebellar ataxia
Brit. Med. J.
(1979)
Cited by (87)
Differential effects of thyrotropin releasing hormone (TRH) on motor execution and motor adaptation process in patients with spinocerebellar degeneration
2020, Journal of the Neurological SciencesCitation Excerpt :Impairment of prism adaptation is not always associated with dysmetria, suggesting these two functions are generated by different mechanisms in the cerebellum [4–6]. Thyrotropin releasing hormone (TRH) was reported to improve cerebellar ataxia [12] and has been widely used as a treatment for cerebellar ataxia in SCD patients in Japan. However, effects of TRH on motor adaptation process have not been studied well.
Endocrine disorders and the cerebellum: from neurodevelopmental injury to late-onset ataxia
2018, Handbook of Clinical NeurologyCitation Excerpt :These effects have been demonstrated in animals (Muroga et al., 1982). Human studies have confirmed that TRH treatment may improve ataxia in some cases (Sobue et al., 1980, 1983). Congenital hypothyroidism is associated with a growth deficit and mental retardation.
Effect of rovatirelin, a novel thyrotropin-releasing hormone analog, on the central noradrenergic system
2015, European Journal of PharmacologyCitation Excerpt :Several pharmacological studies revealed that TRH improves motor dysfunction of various animal models (Faden et al., 1981, 1984; Kurihara et al., 1985; Horita et al., 1986; Yamamoto and Shimizu, 1989). To date, TRH has been clinically investigated for the treatment of spinocerebellar degeneration (SCD), which is a progressive neurodegenerative disorder causing motor dysfunction (Sobue et al., 1983) and has been approved for use in Japan on patients with SCD. However, TRH has certain limitations as a clinical treatment for SCD due to its short biological half-life (4–5 min) in humans, as well as low intestinal and blood–brain barrier permeability (Bassiri and Utiger, 1973; Griffiths, 1976; Kinoshita et al., 1998; Khomane et al., 2011).
Treatment and management issues in ataxic diseases
2012, Handbook of Clinical NeurologyCitation Excerpt :Similar small studies with zolpidem have suggested efficacy (Clauss and Nel, 2004; Clauss et al., 2004). Thyrotropin-releasing hormone (TRH) may also modulate GABA receptors and has shown mild efficacy in animal studies and class I trials (Sobue et al., 1983; Filla et al., 1989; Waragai et al., 1997; Shirasaki et al., 2003; Nakamura et al., 2005). Tanabe Seiyaku Co., Ltd., has marketed an oral TRH formulation (Ceredist) since September 2000, approved in Japan as an orphan drug for spinocerebellar ataxia.
Evaluation of the effect of thyrotropin releasing hormone (TRH) on regional cerebral blood flow in spinocerebellar degeneration using 3DSRT
2009, Journal of the Neurological SciencesNeuropeptides and Their Roles in the Cerebellum
2024, International Journal of Molecular Sciences
- ☆
This work was supported by a grant for the new drug development of the Ministry of Health and Welfare of Japan.
- ∗
Member of the Drug Evaluation Subcommittee in the Research Committee of Therapeutic Agents for Spinocerebellar Degenerations (Chairman: Prof. I. Sobue).